Clinical observation of Shuangxin Formula in the treatment of depression after percutaneous coronary intervention
Objective:To observe the clinical efficacy of Shuangxin Formula in the treatment of depressive state after percutaneous coronary intervention(PCI).Methods:Seventy-two patients who attended outpatient clinics and wards of Dongfang Hospital,Beijing University of Chinese Medicine from April to December 2021 were selected and divided into the control group and the treatment group by randomized number table method,with 36 cases in each group.The control group was treated with western basic therapy plus placebo,and the treatment group was treated with western basic therapy plus Shuangxin Formula granules,and both groups were treated for 4 weeks.Hamilton depression scale 24(HAMD-24),Seattle angina questionnaire(SAQ),self-rating depression scale(SDS)and Pittsburgh sleep quality index(PSQI)scores of the two groups were observed before and after treatment.The levels of PI3K,Akt and GSK3β in peripheral serum were detected by ELISA.Results:Clinical efficacy:Comparing the efficacy of depressive state in the two groups,the total effective rate of the treatment group could reach 94.44％(34/36),which was obviously higher than that of the control group,which was 38.89％(14/36)(P＜0.01).Comparing the angina efficacy of the two groups,the effective rate of the treatment group is 97.22％(35/36),which was obviously higher than that of the control group 33.33％(12/36)(P＜0.01).Main efficacy indexes:the HAMD-24 score in both groups was significantly lower than that before treatment(P＜0.01).After treatment,the HAMD-24 score of the treatment group was significantly lower than that of the control group(P＜0.01),and the difference between the HAMD-24 score before and after treatment of the treatment group was significantly higher than that of the control group(P＜0.0l).The scores of five dimensions of SAQ in both groups were significantly higher after treatment than those before treatment(P＜0.05,P＜0.01).After treatment,the SAQ scores of the treatment group were all significantly higher than those of the control group(P＜0.0l).The difference in SAQ scores before and after treatment was significantly lower in the treatment group than those in the control group(P＜0.01).Secondary efficacy indexes:SDS and PSQI scores of patients after treatment in both groups were lower than those before treatment(P＜0.01,P＜0.05).After treatment,SDS and PSQI scores of the treatment group were significantly lower than those of the control group(P＜0.01).The difference between the SDS and PSQI scores of the treatment group before and after treatment was significantly higher than those of the control group(P＜0.01).Serological indexes:The levels of Akt in the serum of patients in the control group was significantly lower than that before treatment(P＜0.05),and the levels in the serum of PI3K,Akt and GSK3β in the treatment group were significantly lower than that before treatment(P＜0.01).After treatment,the levels of PI3K in the serum of patients in the treatment group was significantly lower than that in the control group(P＜0.05).The differences levels in the serum of PI3K,Akt and GSK3β before and after treatment in the treatment group were significantly higher than those in the control group(P＜0.05,P＜0.01).Conclusion:Shuangxin Formula can relieve depressive state and the degree of angina pectoris of patients,improve the sleep condition,improve the quality of life and reduce the expression of PI3K,Akt and GSK3β in the serum.
Clinical efficacyAfter percutaneous coronary interventionShuangxin FormulaDepressive state
NETL
NSTL
万方数据
